IQVIA HOLDINGS INC（IQV）の決算・業績分析
IQVIA HOLDINGS INCの2025年有価証券報告書をAI分析。売上高$16.3B(+5.9%)。営業利益$2.2B。Industrials。
目次
IQVIA HOLDINGS INCの2025年度 業績サマリー
IQVIA HOLDINGS INC（証券コード: IQV）の2025年度決算・業績分析。売上高は$16.3B（前年比+5.9%）。営業利益は$2.2B（前年比-0.9%）。純利益は$1.4B（前年比-0.9%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
IQVIA HOLDINGS INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- IQVIA achieved $14.4B revenue in FY2024 (+3.9% YoY) and $1.8B operating income (+29.1% YoY), driven by AI-powered healthcare analytics (XBRL).
- Net income rose to $1.1B (+12.9% YoY) with a 7.6% net margin, supported by a 39.3% 5-year CAGR in net income (XBRL).
- ROE of 18.1% and $1.2B in shareholder returns (dividends + buybacks) highlight strong capital allocation (XBRL).
IQVIA HOLDINGS INCの売上高変化の要因
- •Revenue grew to $14.4B in FY2024 (+3.9% YoY), reflecting a 7.6% 5-year CAGR. Historical data shows consistent growth from $10.4B (FY2020) to $15.0B (FY2025 forecast). Operating income surged to $1.8B (+29.1% YoY), driven by AI and analytics adoption. Segment-specific revenue data is not disclosed (XBRL). Growth is attributed to expansion of data analytics, AI solutions, and global healthcare IT infrastructure (10-K).
IQVIA HOLDINGS INCの営業利益変化の要因
- •Operating margin expanded to 12.5% (+1.7% YoY) with $1.8B operating income. EBITDA reached $2.9B (20.3% margin), while net income rose to $1.1B (+12.9% YoY) at a 7.6% net margin. 5-year CAGR for operating income is 21.7%, and net income is 39.3% (XBRL). Cost efficiency improvements and scale from AI-driven operations likely contributed to margin expansion.
IQVIA HOLDINGS INCの事業リスクと対応
Loss/delay of contracts could harm results (10-K).
Underpricing contracts or cost overruns may reduce profits (10-K).
Failure to meet productivity goals in business transformation could harm competitiveness (10-K).
Inability to invest in growth or acquire businesses may impact financial performance (10-K).
Loss of key personnel could disrupt operations (10-K).
Regulatory risks include healthcare reform, prescription limitations, and liability from non-compliance (10-K).
High industry competition and technological disruption pose challenges (10-K).
IQVIA HOLDINGS INCの事業内容
IQVIA provides clinical research, commercial insights, and healthcare intelligence to life sciences and healthcare industries through its IQVIA Connected Intelligence™ platform, leveraging 1.2B non-identified patient records and AI analytics (10-K). Key offerings include analytics-driven clinical development, real-world solutions, and proprietary applications. With ~88,000 employees globally, the company serves biotech, pharma, medical device firms, researchers, and payers without significant customer concentration (10-K). Competitive advantages include its largest healthcare data collection, advanced analytics, and AI integration with privacy safeguards (10-K).
IQVIA HOLDINGS INCのAI業績分析レポート（2024年度）
IQVIA HOLDINGS INC. (IQV) FY2024 Annual Report Analysis
Highlights
Business Overview
IQVIA provides clinical research, commercial insights, and healthcare intelligence via AI and analytics (10-K). Key offerings include analytics-driven clinical development, real-world solutions, and IQVIA Connected Intelligence™. With ~88,000 employees, the company serves biotech, pharma, and payers without significant customer concentration. Competitive advantages include its largest healthcare data collection (1.2B patient records) and AI integration (10-K).
Revenue Analysis
Revenue grew to $14.4B (+3.9% YoY), with a 7.6% 5-year CAGR. Operating income surged to $1.8B (+29.1% YoY). Historical data shows consistent growth from $10.4B (FY2020) to $15.0B (FY2025 forecast). Segment-specific revenue data is not disclosed (XBRL). Growth is driven by AI and analytics adoption (10-K).
Profitability Analysis
Operating margin expanded to 12.5% (+1.7% YoY) with $1.8B operating income. EBITDA reached $2.9B (20.3% margin). Net income rose to $1.1B (+12.9% YoY) at a 7.6% net margin. 5-year CAGR for operating income is 21.7%, and net income is 39.3% (XBRL).
Balance Sheet Analysis
Equity ratio is 22.6% with $6.0B total equity. Long-term debt is $13.0B, resulting in a 3.40x debt-to-equity ratio and $11.6B net debt (4.0x EBITDA). Current ratio is 0.86x, indicating potential liquidity challenges. Cash reserves are $1.4B (XBRL).
Cash Flow Analysis
Operating cash flow was $2.3B, with $254M free cash flow (FCF). Investing cash flow was -$2.0B, and financing cash flow was -$329M, including $1.2B in share repurchases (XBRL). D&A totaled $1.1B.
Working Capital Analysis
N/A — No data on receivables, inventory, or payables days is available (XBRL).
Risks
Outlook
N/A — No management guidance or forward-looking trends are explicitly mentioned in the 10-K (10-K).
Industrialsの企業一覧
IQVIA HOLDINGS INCと同じ「Industrials」セクターの企業